Please login to the form below

Not currently logged in
Email:
Password:

Afinitor

This page shows the latest Afinitor news and features for those working in and with pharma, biotech and healthcare.

Merck & Co announces results at ASCO for Keytruda plus Lenvima for kidney cancer patients

Merck & Co announces results at ASCO for Keytruda plus Lenvima for kidney cancer patients

Novartis’ Afinitor (everolimus) versus Sutent (sunitinib) for the first-line treatment of advanced RCC patients. ... In addition, Lenvima plus Afinitor also demonstrated similar changes from baseline at week 46 on 14 out of 18 HRQoL and disease-related

Latest news

More from news
Approximately 13 fully matching, plus 53 partially matching documents found.

Latest Intelligence

  • Back to the future Back to the future

    The successes of Gilenya, Afinitor/Votubia, Galvus, Tasigna and Jakavi - as well as its generics arm, Sandoz - mean that Novartis is now less than $500m behind Pfizer in second place.

  • Pharma deals during April 2014 Pharma deals during April 2014

    Novartis' pipeline includes more than 25 new molecular entities targeting key oncogenic pathways including: Gleevec and its follow-up Tasigna (blood-cancer); Afinitor (kidney cancer and recently approved for breast cancer);

  • Interview: Joseph Jimenez, Novartis Interview: Joseph Jimenez, Novartis

    In 2010, we had 13 key product approvals and 16 major filings in pharma, including Gilenya, Lucentis and Afinitor," he points out. ... populations. "In Q2 alone, we had four major approvals and two major filings, including Afinitor, Arcapta Neohaler,

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • Oncology drugs under AMNOG

    patients the comparator was a different targeted therapy, Afinitor (everolimus), rather than Nexavar - although for cytokine-pretreated patients the trial comparator could be used.The G-BA still exercises its right

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Oxford University Press

Oxford University Press publishes over 100 prestigious, highly cited, and authoritative medical journals, many in collaboration with some of the...

Latest intelligence

JulAug cover image
The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
Chris Ross conducts a literary-inspired review of pharma’s pursuit of communications excellence...
The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals...
Virtual Speaker Program: A Customer Story
Learn how we helped our client develop a virtual speaker program and roll out a series of regional peer-to-peer education sessions....